Altruist Biologics’ Perfusion Bioprocessing Platform: Accelerating Biologics Development Through Continuous Innovation

Mammalian cell culture has become the cornerstone of therapeutic protein production, with CHO cells serving as the predominant host for complex biologics requiring sophisticated post-translational modifications. Among available culture modalities—batch, fed-batch, intensified fed-batch (IFB), and perfusion—perfusion technology stands out for its ability to sustain high viable cell densities, while enabling continuous product harvesting. This translates directly into higher volumetric productivity, smaller footprint requirements, and enhanced flexibility for labile molecules.

This whitepaper presents the strategic advantages of perfusion technology in biologics manufacturing, Altruist’s comprehensive perfusion platform capabilities, and three representative case studies demonstrating yield improvement, quality optimization, and process intensification.